Canada Markets open in 1 hr 41 mins

ARDS Dec 2022 7.500 call

OPR - OPR Delayed Price. Currency in USD
Add to watchlist
0.35000.0000 (0.00%)
As of 11:06AM EST. Market open.
Full screen
Previous Close0.3500
OpenN/A
Bid0.0000
Ask0.3000
Strike7.50
Expire Date2022-12-16
Day's Range0.3500 - 0.3500
Contract RangeN/A
VolumeN/A
Open Interest52
  • GlobeNewswire

    Aridis to Participate in Key Opinion Leader Discussion on Immunotherapy for Infectious Diseases

    The Company’s superiority Phase 3 ‘ASAP-1' study of AR-301 monoclonal antibody in S. aureus pneumonia and the pending data readout will be a focus of the KOL event Los Gatos, Calif., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, today announced its participation in H.C. Wainwright & Co.’s 2022 KOL Series (Part 8) on Tues

  • Zacks

    Aridis Pharmaceuticals (ARDS) Reports Q3 Loss, Misses Revenue Estimates

    Aridis Pharmaceuticals (ARDS) delivered earnings and revenue surprises of -4,100% and 96.44%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Aridis Pharmaceuticals Announces Third Quarter 2022 Financial Results and Business Update

    Top-line data from the Phase 3 clinical trial evaluating AR-301 for the treatment of VAP expected in December of this year LOS GATOS, Calif., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, today reported financial and corporate results for its third quarter ended September 30, 2022. Third Quarter Highlights Closed enrollm